[Advances in clinical research on novel BTK inhibitors for the treatment of chronic lymphocytic leukemia].
作者信息
Qiu T L, Miao Y, Li J Y
机构信息
Department of Hematology, Key Laboratory of Nanjing Medical University, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 Nov 14;44(11):963-968. doi: 10.3760/cma.j.issn.0253-2727.2023.11.015.
Abstract
摘要
相似文献
1
[Advances in clinical research on novel BTK inhibitors for the treatment of chronic lymphocytic leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2023 Nov 14;44(11):963-968. doi: 10.3760/cma.j.issn.0253-2727.2023.11.015.
2
An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Expert Rev Hematol. 2020 Oct;13(10):1039-1046. doi: 10.1080/17474086.2020.1817735. Epub 2020 Sep 14.
3
Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Curr Treat Options Oncol. 2023 Sep;24(9):1259-1273. doi: 10.1007/s11864-023-01112-0. Epub 2023 Jul 6.
4
BTK Inhibitors in Chronic Lymphocytic Leukemia.
Curr Hematol Malig Rep. 2021 Oct;16(5):422-432. doi: 10.1007/s11899-021-00645-1. Epub 2021 Oct 2.
5
BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Curr Treat Options Oncol. 2021 Jun 10;22(8):66. doi: 10.1007/s11864-021-00862-z.
6
[Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research].
Zhonghua Xue Ye Xue Za Zhi. 2023 May 14;44(5):380-387. doi: 10.3760/cma.j.issn.0253-2727.2023.05.005.
7
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).
Genes (Basel). 2023 Dec 6;14(12):2182. doi: 10.3390/genes14122182.
8
Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Expert Rev Hematol. 2024 Jun;17(6):201-210. doi: 10.1080/17474086.2024.2356257. Epub 2024 May 24.
9
Noncatalytic Bruton's tyrosine kinase activates PLCγ variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.
J Biol Chem. 2020 Apr 24;295(17):5717-5736. doi: 10.1074/jbc.RA119.011946. Epub 2020 Mar 17.
10
Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse.
Semin Oncol Nurs. 2021 Aug;37(4):151177. doi: 10.1016/j.soncn.2021.151177. Epub 2021 Jul 16.
本文引用的文献
1
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
Am J Hematol. 2023 Apr;98(4):571-579. doi: 10.1002/ajh.26826. Epub 2023 Jan 22.
2
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13.
3
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
J Clin Oncol. 2023 Feb 10;41(5):1035-1045. doi: 10.1200/JCO.22.00510. Epub 2022 Nov 17.
4
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol. 2022 Aug;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5. Epub 2022 Jul 7.
5
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
J Natl Compr Canc Netw. 2022 Jun;20(6):622-634. doi: 10.6004/jnccn.2022.0031.
6
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
N Engl J Med. 2022 Feb 24;386(8):735-743. doi: 10.1056/NEJMoa2114110.
7
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1.
8
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Br J Haematol. 2022 Mar;196(5):1209-1218. doi: 10.1111/bjh.17994. Epub 2021 Dec 16.
9
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Lancet Haematol. 2021 Dec;8(12):e879-e890. doi: 10.1016/S2352-3026(21)00307-0.
10
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Am J Hematol. 2021 Dec 1;96(12):1679-1705. doi: 10.1002/ajh.26367.
Zotero 插件